Advertisement

BMC Cardiovascular Disorders

, 19:279 | Cite as

Apolipoprotein M and sphingosine-1-phosphate complex alleviates TNF-α-induced endothelial cell injury and inflammation through PI3K/AKT signaling pathway

  • Yang LiuEmail author
  • Li Tie
Open Access
Research article
Part of the following topical collections:
  1. Epidemiology

Abstract

Background

In spite of the important role of Apolipoprotein-M (ApoM) and Sphingosine-1-Phosphate (S1P) played in atherosclerosis (AS), there was few related research reporting ApoM and S1P complex (ApoM-S1P) on biological activities of human umbilical vein endothelial cells (HUVECs). In this study, we explored the effect and mechanism of ApoM-S1P on TNF-α-induced inflammation in HUVECs.

Methods

TNF-α was utilized to induce HUVEC injury and inflammation. After HUVECs were treated with antagonists of ApoM, S1P, ApoM + S1P, and ApoM + S1P + S1PR, calcein-acetoxymethyl ester was employed for the assessment of the adhesion of HUVECs to THP-1, immunofluorescence for the observation of caspase-1expression in HUVECs, reactive oxygen species (ROS) kit for the detection of ROS level in HUVECs. The impact of TNF-α, ApoM, S1P and S1PR antagonists on inflammatory response, pyroptosis and adhesion of THP-1 monocytes to HUVECs were determined by detecting expressions of pyroptosis related proteins (IL-1β, IL-18, ASC, NLRP3 and caspase-1), inflammatory cytokines (IL-6 and IL-10), adhesion molecules (E-selectin, ICAM-1, and VCAM-1) and p-PI3K/p-AKT by qRT-PCR and Western blot, as well as by ELISA.

Results

TNF-α could increase adhesion of THP-1 monocytes to HUVECs and induce inflammatory response and pyroptosis in HUVECs, indicated by up-regulated expressions of E-selectin, ICAM-1, VCAM-1, IL-1β, IL-18, caspase-1, ASC, NLRP3, and IL-6, and down-regulated expression of IL-10. Co-treatment of ApoM-S1P on TNF-α treated HUVECs could protect HUVECs from injury and inflammation, evidenced by the attenuation of expressions of pyroptosis related proteins, inflammatory cytokines, and adhesion molecules, as well as the augment of PI3K and AKT phosphorylation. JTE-013, an antagonist of S1PR2, could reverse the amelioration of ApoM-S1P on pyroptosis and inflammation of HUVECs, indicating that ApoM-S1P could bind to S1PR2 to protect HUVECs from injury and inflammation through activating PI3K/AKT pathway.

Conclusion

ApoM-S1P could attenuate TNF-α induced injury and inflammatory response in HUVECs by binding to S1PR2 to activate PI3K/AKT pathway.

Keywords

Pyroptosis TNF-α ApoM S1P PI3K/AKT Inflammation Human umbilical vein endothelial cells 

Abbreviations

ApoM

Apolipoprotein-M

ApoM-S1P

ApoM and S1P complex

AS

Atherosclerosis

ELISA

Enzyme-linked Immunosorbent assay

FBS

Fetal bovine serum

HDL

High-density lipoprotein

HUVECs

Human umbilical vein endothelial cells

qRT-PCR

Quantitative real-time polymerase chain reaction

ROS

Detection of reactive oxygen species

S1P

Sphingosine-1-phosphate

S1PR1

S1P receptor 1

Background

Atherosclerosis (AS) is a widespread disease that causes morbidity and mortality, which could deteriorate into circulatory problems including cerebrovascular disease and coronary disease [1, 2]. Despite the great advancement on both basic and clinical researches, the incidence of AS has been increased dramatically in recent decades and has resulted in millions of deaths around the world each year [3, 4]. AS is characterized by the sedimentation of fibrous tissues and lipids in the intima of elastic arteries, with consequent formation of thrombus and structural damage caused by thickening and hardening of the vessel walls [5]. Previous study has unraveled that cell death and inflammation play critical roles in various stages of AS [6]. Typically, cell death is especially attributed to apoptosis and necrosis, nevertheless, other forms of cell death including pyroptosis has also been discovered [7]. Pyroptosis is a new type of pro-inflammatory programmed cell death different from apoptosis and necrosis, which can lead to cytokines release and activate pro-inflammatory immune cell mediators [8, 9]. However, the roles of pyroptosis and its potential relationship with AS as well as the underlying mechanisms remained inadequately investigated.

Sphingosine-1-phosphate (S1P) is a membrane-derived sphingolipid that regulates a variety of cellular processes including migration, growth, inflammation, survival, and angiogenesis, and is considered as a key regulator of AS physiology and pathophysiology [10, 11]. Up-regulated expression of pro-inflammatory cytokine IL-6 is proved to increase S1P at cellular level, which consequently results in elevated expression of S1P receptor 1 (S1PR1) in sickle cell disease mice models [12]. S1P signaling exerts a critical impact on lymphocyte transportation, blood vessel development, and neurogenesis and S1P receptor antagonist has been approved for the control of autoimmune neuroinflammation in patients with multiple sclerosis [13]. Inhibition of endothelial S1PR2 signaling attenuates endothelial senescence associated with functional impairment and endothelial activation induced by atherogenic stimulation [14]. As a carrier for S1P, apolipoprotein M (ApoM) is one of the apolipoprotein components of high-density lipoprotein (HDL), processing atheroprotective function by regulating cholesterol efflux [15, 16]. The implication of ApoM and S1P in AS has been evidenced in rodent models [17]. Nevertheless, the impact of ApoM-S1P complex (ApoM-S1P) in AS is presently controversial [18]. Data in recent study demonstrated that pyroptosis may be associated with AS by affecting the stability of atherosclerotic lesion [5]. Considering the important role of ApoM-S1P in AS, it is possible that ApoM-S1P may regulate pyroptosis through certain pathway in AS, while no such studies verified our hypothesis. Here, we assessed the impact of ApoM-S1P on injury and inflammation of HUVECs and its possible mechanism. In this study, we discovered that ApoM-S1P could inhibit TNF-α-induced inflammation and pyroptosis of HUVECs via binding S1PR2 to activate the PI3K/AKT pathway.

Methods

Cell culture

Human umbilical vein endothelial cells (HUVECs) and THP-1 monocytes were acquired from Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China). HUVECs were nurtured in DMEM medium comprising 1% penicillin/streptomycin and 10% fetal bovine serum (FBS). When HUVECs were fused into monolayer cells, they were passaged with 0.125% pancreatin-0.02% EDTA digestion. The 3-5th generations of HUVECs were used for experiments. HUVECs were starved for 10 h in DMEM medium containing 1% FBS before being pre-treated with tumor necrosis factor-α (TNF-α, 50 ng/mL, Peprotech, Rocky Hill, NJ, USA) for 6 h [19, 20]. THP-1 monocytes were incubated in RPMI-1640 medium, supplemented with 1% penicillin and streptomycin, 10% FBS, 1% L-glutamine, 1% HEPES buffer and 0.05 mM β-mercaptoethanol. Both HUVECs and THP-1 monocytes were nurtured at 37 °C in a 5% CO2 incubator.

Load ApoM with S1P

An eight-folds of S1P (Cayman, Ann Arbor, MI, USA) was added to ApoM (Abnova, Taiwan, China) and incubated for 30 min at room temperature to load ApoM with S1P. Unbound S1P was removed using a desalting PD10 column (GE Healthcare, Beijing, China) after the mixture was incubated with serum-free M200 medium. Then ApoM-S1P was diluted to 0.5 μM and stored at  -20 °C.

THP-1-HUVECs adhesion assays

Before adhesion assays, HUVECs were pretreated with 50 ng/mL of TNF-α for 6 h. Then HUVECs were treated with ApoM (1.0 μM), S1P (1.0 μM), or ApoM-S1P for 24 h [21] and grouped into TNF-α group, Control group, TNF-α + ApoM group, TNF-α + S1P group, and TNF-α + ApoM + S1P group. Antagonists for S1P receptors (S1PR1, S1PR2 and S1PR3) were added in TNF-α stimulated HUVECs for 30 min before cells were subjected to ApoM-S1P treatment. According to antagonist treatment, cells were grouped into TNF-α + ApoM + S1P + W146 group, TNF-α + ApoM + S1P + JTE-013 group, and TNF-α + ApoM+S1P + CAY10444 group, respectively.

THP-1 monocytes were labeled with 5 μmol/L calcein-acetoxymethyl ester (Thermo Fisher Scientific, Waltham, MA, USA) and cultured in the incubator for 30 min. The labeled cells were washed twice with PBS and re-suspended in serum-free medium. Then culture medium of HUVECs was removed. The resuspensions of labeled THP-1 monocytes were added onto monolayers of HUVECs. After 1 h incubation, the plates were rinsed twice with medium without serum. The adherent THP-1 monocytes on HUVECs were counted with a fluorescence microscope (Olympus IX71, Tokyo, Japan). The culture dish was divided into four quadrants according to its diameter. For each quadrant, one 200 × visual field in the middle of the quadrant was chosen for analysis. The average number of the four quadrants was identified as the number of adherent THP-1 monocytes.

Quantitative real-time polymerase chain reaction (qRT-PCR)

Total RNA of HUVECs was extracted by RNeasyPlus Micro (Qiagen, dusseldorf, Germany). The ratio of OD260 nm to OD280 nm was measured to quantify and test the purity of RNA. Reverse Transcription of RNA into cDNA was conducted by Reverse Transcription System (Promega, Madison, WI, USA). The mRNA expression levels of E-selectin, ICAM-1, VCAM-1, IL-1β, IL-18, caspase-1, ASC, NLRP3, IL-6, and IL-10 were detected by qRT-PCR using SYBR Premix ExTaq (Takara Bio, Inc., Otsu, Japan). GAPDH was regarded as internal reference. All tests were conducted in triplicates. All data and figures were depicted as the mean ± standard deviation (SD), and data analysis was employed the 2-ΔΔCt method [22]. The amplified primer sequences of each gene and its primers are shown in Table 1.
Table 1

Primer sequences information

Name

Primer

E-selectin

F: 5′-ATGTGAAGCTGTGAGATGCG-3’

R: 5′-CCACTGCAGCTCATGTTGAT-3’

ICAM-1

F: 5′-AGACATAGCCCCACCATGAG-3’

R: 5′-CAAGGGTTGGGGTCAGTAGA-3’

VCAM-1

F: 5′-TCGCTCAAATCGGTGACTCC-3’

R: 5′-ACTTCGTTCCAGCTTCCCAG-3’

IL-1β

F: 5′-GCAGGCAGTATCACTCATTGTGG-3’

R: 5′-GAGTCACAGAGGATGGGCTCTTC-3’

IL-18

F: 5′-ACCCCAGAAGAGAGGGAGTC-3’

R: 5′-GTAGATGGTGGAATCGGCGT-3’

caspase-1

F: 5′-CACGAGACCTGTGCGATCAT-3’

R: 5′-CTTGAGGGAACCACTCGGTC-3’

ASC

F: 5′-GTCCAGGTTCCGCCCC-3’

R: 5′-AACTTCTTGAGCTCCTCGGC-3’

NLRP3

F: 5′-AAACGACCTTCATCCCCACC-3’

R: 5′-CAGGACTGCCCTCCTCTAGT-3’

IL-6

F: 5′-GAGGAGACTTCACAGAGGATACCAC-3’

R: 5′-TTGCCATTGCACAACTCTTTTC-3’

IL-10

F: 5′-CCAACGAACCGTCCCTGTTA-3’

R: 5′-TCGGAGTTGTGAGCTTCCAC-3’

GAPDH

F: 5′-TCTTGTGCAGTGCCAGCCT-3’

R: 5′-TGAGGTCAATGAAGGGGTCG-3’

Notes: F Forward primer, R Reversed primer

Western blotting

Cell lysates were made from HUVECs using RIPA buffer comprising phosphatase inhibitors (Cayman Chemical, Ann Arbor, MI, USA) and Halt protease inhibitors (Pierce, Rockford, IL, USA). Bradford assay was adopted to test the concentration of proteins. The cell lysates were mixed with loading buffer and separated on a 10% SDS polyacrylamide gels. The proteins on gels were then transferred onto PVDF membrane. The membranes were blocked in TBST containing 0.05 g/mL BSA for 1 h. After blocking, the membranes were incubated overnight at 4 °C with primary antibodies (abcam, san francsico, USA), rabbit-derived GAPDH (1:10000, ab181602), E-selectin (1:200, ab18981), VCAM-1 (1:2000, ab134047), ICAM-1 (1:2000, ab53013), caspase-1(1:500, ab138483), NLRP3 (1:500, ab214185), ASC (1:1000, ab155970), PI3K (1:1000, ab191606), p-PI3K (1:1000, ab182651), AKT (1:10000, ab179463), p-AKT (T308, 1:1000, ab38449) and p-AKT (Ser473,1:2000, 4060 T, Cell Signaling Technology, Boston, USA). The membranes were washed in TBST and then incubated at room temperature for 2 h with goat anti-rabbit IgG (1:5000, Beijing ComWin Biotech Co., Ltd., Beijing, China). The membranes were then rinsed three times with TBST. ECL luminescent solution was used before a chemiluminecence imaging analysis system (GE Healthcare, USA) was applied for observation.

Enzyme-linked Immunosorbent assay (ELISA)

The supernatants from untreated and treated HUVECs were centrifuged (300 g, 5 min) and cell-free supernatants were frozen at  -80 °C until usage. The assays were conducted utilizing commercial ELISA kits (abcam, san francsico, USA) in duplicates, according to the manufacturers’ instructions. The microplate absorbance reader (Tecan, Groening, Austria) was employed to measure the absorbance at 450 nm. Standard curves were applied to calculate the concentrations of analytes.

Immunofluorescence

HUVECs were seeded in 24-well plates at the density of 5 × 103 cells/well, followed by fixation in 4% paraformaldehyde for 15 min, permeation with 0.5% triton-X-100 for 20 min, and incubation with appropriate concentration of primary antibody of caspase-1 (1:500, ab1872, abcam, san francsico, USA) overnight at 4 °C. After that, sections were incubated with secondary antibody of Alexa Fluor 488-labeled goat anti-rabbit IgG (ab150077, 1:2000, abcam, MA, USA) for 45 min avoiding light, prior to PBS rinsing. Then cells were stained with 0.5 μg/mL of DAPI for 15 min avoiding light, and washed with PBS. Subsequently, sections were sealed and observed under a fluorescence microscope (Olympus IX71, Tokyo, Japan).

Detection of reactive oxygen species (ROS)

The ROS was measured using DCF-DA kit (BestBio, Shanghai, China) according to the manufacturer’s instructions. Cells (1 × 107/mL) were labeled with 10 μM of fluorescent probe DCFH-DA, followed by incubation in an incubator for 20 min at 37 °C, and serum-free cell culture solution washing for three times. The fluorescence activity was analyzed by fluorescence microscopy with an excitation wavelength of 488 nm and an emission wavelength of 520 nm. The amount of intracellular ROS was proportional to the fluorescence intensity of DCF, and the fluorescence intensity indicated the ROS level.

Statistical analysis

All data were analyzed using SPSS 17.0 software (SPSS, Chicago, IL, USA) and GraphPad Prism 6.0. T test was used for comparison between two groups, and differences among groups were analyzed using One-way analysis of variance. P < 0.05 was regarded as a statistically significant difference.

Results

TNF-α enhances the adhesion of HUVECs and induces pyroptosis

In the early stages of AS, endothelial cell function is impaired, and the expression of adhesion molecules is significantly increased, thereby recruiting pro-inflammatory immune cells to adhere to the vascular wall [23]. In this study, we discovered that the number of THP-1 monocytes adhering to the surface of HUVECs in the TNF-α group was significantly increased compared with the Control group (Fig. 1a), and up-regulate the mRNA and protein levels of adhesion molecules E-selectin, ICAM-1, VCAM-1 (P < 0.001) (Fig. 1b-c). ELISA illustrated that the contents of three adhesion molecules in TNF-α group were higher than those in the Control group (P < 0.05) (Fig. 1d). All these stated that TNF-α could enhance the adhesion function of HUVECs and induce the generation of adhesion molecules.

Pyroptosis is a more recently identified pathway of programmed cell death and accompanied with the severe inflammation response [24]. The detection on effect of TNF-α treatment on pyroptosis of HUVECs displayed that the mRNA levels of caspase-1, ASC, NLRP3, IL-1β and IL-18 in TNF-α group were higher than those in Control group, while anti-inflammatory cytokine were lower than Control group (P < 0.01) (Fig. 1e). Consistent expression pattern was found on protein expressions of pyroptosis and inflammation related factors (P < 0.05) (Fig. 1f). ELISA results manifested that compared with Control group, the contents of IL-1β, IL-18, and pro-inflammatory cytokine IL-6 in TNF-α group were increased, while the content of anti-inflammatory cytokine IL-10 was decreased (P < 0.01) (Fig. 1g). Subsequently, immunofluorescence was utilized to inspect the expression of caspase-1 in HUVECs. The results manifested that TNF-α group had higher caspase-1 expression than the Control group (Fig. 1h). Meanwhile, DCF-DA kit detection results described that there was elevated ROS level in TNF-α group in comparison to the Control group (P < 0.001) (Fig. 1i). These indicated that TNF-α could enhance inflammation and promote pyroptosis of HUVECs.
Fig. 1

TNF-α enhances the adhesion function and induce pyroptosis of HUVECs

Notes: After stimulating HUVECs with TNF-α treatment, fluorescence microscope was applied to observe the number of adhesion of THP-1 to HUVECs (200 ×) (a); The effect of TNF-α on mRNA and protein levels of ICAM-1, E-selectin, and VCAM-1 were inspected by qRT-PCR (b), Western blot (c) and ELISA (d); The effect of TNF-α on pyroptosis was determined by qRT-PCR (e), western blot (f) and ELISA (g) to detect the expression levels of IL-1β, IL-18, caspase-1, ASC, NLRP3, IL-6, and IL-10; The expression of caspase-1 was performed by immunofluorescence (h), and ROS level was measured by DCF-DA kit (I); Data were presented as mean ± SD, **P < 0.01 ***P < 0.001 compared to the Control group; HUVECs, human umbilical vein endothelial cells; SD, standard deviation

ApoM-S1P reduces cell adhesion and pyroptosis induced by TNF-α

ApoM, a specific S1P chaperone, is a novel apolipoprotein associated with anti-inflammatory functions [25]. Study has illustrated the effect of ApoM-S1P in mediating anti-inflammatory effects on endothelial cells [23]. Hence, we investigated whether ApoM-S1P treatment could affect TNF-α-induced adhesion and pyroptosis of HUVECs. Fluorescence microscope observed that compared with the TNF-α + ApoM group or TNF-α + S1P group, TNF-α + ApoM + S1P group had suppressed adhesion quantity of THP-1 monocytes (P < 0.001) (Fig. 2a). In addition, ApoM-S1P treatment could substantially decrease the protein expression levels of VCAM-1, E-selectin, and ICAM-1 (P < 0.01). While there were no significant changes of adhesion quantity of THP-1 monocytes in both TNF-α + ApoM group and TNF-α + S1P group in comparison to that in TNF-α group (P > 0.05) (Fig. 2b-d). In addition, qRT-PCR results explained that TNF-α + ApoM + S1P group had a suppressed the mRNA levels of IL-1β, IL-18, caspase-1, ASC, NLRP3 and IL-6, and an elevated mRNA level of IL-10 than TNF-α + ApoM group or TNF-α + S1P group (P < 0.01) (Fig. 2e). The results obtained by Western blot and ELISA supported the protective effect of ApoM + S1P on pyroptosis and inflammation of HUVECs (P < 0.01) (Fig. 2f-g). In addition, compared with TNF-α group, no significant difference was revealed in TNF-α + ApoM group and TNF-α + S1P group (P > 0.05) (Fig. 2e-g). Then immunofluorescence was employed to assay caspase-1 expression in HUVECs. The results presented that TNF-α + ApoM+S1P group had heightened caspase-1 expression compared with the TNF-α + ApoM group or TNF-α + S1P group (Fig. 2h), whereas caspase-1 expression showed no obvious difference in cells treated with ApoM or S1P alone when compared with cells in TNF-α group (TNF-α + ApoM group or TNF-α + S1P group vs TNF-α group; P > 0.05) (Fig. 2h). Meanwhile, DCF-DA kit detection results displayed that TNF-α + ApoM+S1P group had elevated ROS level in comparison to TNF-α + ApoM group or TNF-α + S1P group (P < 0.001) (Fig. 2i), and there was no significant difference of ROS level in either TNF-α + ApoM group, or TNF-α + S1P group when compared with TNF-α group (P > 0.05). These results indicated that ApoM-S1P can observably reduce TNF-α-induced adhesion and cell pyroptosis.
Fig. 2

ApoM-S1P dramatically reduces TNF-α induced cell adhesion and pyroptosis

Notes: After TNF-α stimulated HUVECs were treated with ApoM-S1P, the adhesion of THP-1 monocytes to HUVECs were counted under a fluorescence microscopy (200 ×) (a); The impact of ApoM-S1P on expressions of adhesion molecules E-selectin, ICAM-1, VCAM-1 were determined by qRT-PCR (b), Western blot (c) and ELISA (d); the expressions of pyroptosis and inflammatory related cytokines IL-1β, IL-18, caspase-1, ASC, NLRP3, IL-6, and IL-10 were verified after cells were subjected to ApoM-S1P treatment by qRT-PCR (e), Western blot (f) and ELISA (g); Immunofluorescence was used to assay caspase-1 expression (h), and ROS level evaluated by DCF-DA kit (i); Data were presented as mean ± SD, **P < 0.01 ***P < 0.001 compared to the TNF-α + ApoM group; ##P < 0.01 ###P < 0.001 compared to TNF-α + S1P group; HUVECs, human umbilical vein endothelial cells

ApoM-S1P inhibits TNF-α-induced adhesion and pyroptosis via S1PR2

To further investigate the mechanism of ApoM+S1P inhibition on inflammatory factors and adhesion molecules, TNF-α-induced HUVECs were pretreated with specific S1PR1 antagonist W146, S1PR2 antagonist JTE-013, or S1PR3 antagonist CAY10444 for 30 min before ApoM-S1P treatment. Compared with TNF-α + ApoM + S1P group, TNF-α + ApoM + S1P + JTE-013 group had an elevated adhesion quantity of THP-1 monocytes, while TNF-α + ApoM + S1P + W146 group and TNF-α + ApoM + S1P + CAY10444 group showed no difference with TNF-α + ApoM+S1P group (Fig. 3a). Detection on adhesion molecules demonstrated that E-selectin, ICAM-1 and VCAM-1 were increased after JTE-013 treatment in comparison to TNF-α + ApoM + S1P group (Fig. 3b-c). Results also demonstrated that JTE-013 could reverse the protective impact of ApoM + S1P on pyroptosis of HUVECs, evidenced by increased IL-1β, IL-18 and IL-6, and decreased expression of IL-10 (P < 0.001) (Fig. 3d). No substantial difference was uncovered for TNF-α + ApoM + S1P + W146 group and TNF-α + ApoM + S1P + CAY10444 group when compared with TNF-α + ApoM + S1P group. Subsequently, DCF-DA kit detection results manifested that JTE-013 group had elevated ROS level in comparison to TNF-α + ApoM + S1P group (P < 0.001) (Fig. 3e), and there was no markedly difference of ROS level between W146 group, CAY10444 group, and TNF-α + ApoM + S1P group (P > 0.05). These results indicate that ApoM-S1P inhibits TNF-α-induced adhesion and cell pyroptosis by binding to S1PR2.
Fig. 3

ApoM-S1P inhibits TNF-α induced adhesion and pyroptosis through binding to S1PR2. Notes: To explore the downstream mechanism of ApoM-S1P on attenuation of pyroptosis and inflammatory response of HUVECs, S1PR2 antagonist was added in TNF-α stimulated HUVECs before cells were subjected to ApoM-S1P treatment. Fluorescence microscope was used to count the number of adhesion of THP-1 monocytes (200 ×) (a); The mRNA and protein levels of E-selectin, ICAM-1, and VCAM-1in HUVECs were detected by qRT-PCR (b) and Western blot (c); ELISA was utilized to test the contents of IL-1β, IL-18, IL-6, and IL-10 (d); DCF-DA kit for inspection of ROS level (e); Data are displayed as mean ± SD, **P < 0.01 ***P < 0.001 compared to the TNF-α + ApoM + S1P + JTE-013 group; HUVECs, human umbilical vein endothelial cells; SD, standard deviation

ApoM-S1P plays a protective role through PI3K/AKT signaling pathway

Previous evidence has demonstrated that PI3K/AKT is a downstream signaling pathway of S1P [26]. Therefore, we hypothesized that ApoM+S1P may exert its protective role in AS though PI3K/AKT signaling pathway. In this regards, we detected the effect of ApoM, S1P or/and SIPR2 antagonist JTE-013 on phosphorylation level of PI3K and AKT with the application of Western blot. The analysis revealed that TNF-α group had a lower phosphorylation level of PI3K and AKT than Control group. TNF-α + ApoM + S1P could partially restore the phosphorylation level of PI3K and AKT when compared with TNF-α group, while SIPR2 antagonist JTE-013 could inhibit the phosphorylation level of PI3K and AKT in comparison to ApoM-S1P treatment alone (P < 0.001). The phosphorylation level of PI3K and AKT in TNF-α + ApoM + S1P group was substantially higher than those in TNF-α + ApoM group and TNF-α + S1P group (P < 0.001) (Fig. 4). These indicated that ApoM-S1P could reverse the inhibitory effect of TNF-α on PI3K/AKT signaling pathway via mediating SIPR2.
Fig. 4

ApoM-S1P activates PI3K/AKT signaling pathway to attenuate pyroptosis and inflammatory response of HUVECs. Note: The detection of phosphorylation level of PI3K and AKT by Western blot. Data were shown as mean ± SD, **P < 0.001 compared to the Control group, ***P < 0.001 compared to the TNF-α + ApoM group, ***P < 0.001 compared to TNF-α + ApoM+S1P group; HUVECs, human umbilical vein endothelial cells; SD, standard deviation

Discussion

TNF-α is a critical inflammatory factor that has been displayed to cause the interaction between vascular endothelial cells and invading monocytes [20]. TNF-α also plays a crucial role in atherosclerotic inflammatory cascade through up-regulation expression of adhesion molecule, activation of endothelial cell, and remodeling of vascular [27]. In the current study, HUVECs was firstly stimulated by TNF-α and then subjected to ApoM, SIP, or ApoM-S1P treatment to observe the changes on expression levels of cell adhesion, inflammation, and pyroptosis related factors. Our study displayed that ApoM-S1P could markedly down-regulate the expression of the pro-inflammatory cytokine, adhesion molecules, and pyroptosis related proteins by binding to S1PR2 so as to active the PI3K/AKT signaling pathway, thereby inhibiting the inflammatory response and pyroptosis of TNF-α-induced HUVECs.

ApoM-S1P has recently been proved to possess unique anti-inflammatory effects [18]. In this study, we discovered that ApoM-S1P exerts a crucial prestige on inflammatory response and pyroptosis of TNF-α induced HUVECs. Previous results support the implication of ApoM-S1P in various diseases. For example, ApoM-S1P has a major influence on diet-induced obesity and postprandial triglyceride metabolism [28]. Furthermore, ApoM-S1P is a pivotal element of anti-apoptotic activity of HDLs, which can promote the optimization of endothelial function [29]. Another research illustrated that ApoM-S1P is a therapeutic target for endothelial barrier dysfunction [30]. In addition, AS is reported to be associated with inflammatory processes in the endothelial cells of the vessel wall [31]. Consistent with results from previous study, we found ApoM-S1P could attenuate cell adhesion, inflammation and pyroptosis of HUVECs, therefore may also beneficial to attenuate AS progression. To further explore the mechanism herein, S1PR antagonist was added in TNF-α induced HUVECs before ApoM-S1P treatment. S1P regulates various biological activities by binding to different G-protein-coupled receptors known as S1PR1-S1PR5 [32]. Here, we observed that the S1PR2 antagonist reverse the protective effect of ApoM-S1P on pyroptosis and inflammation, presented by increased expressions of IL-1β, IL-18, IL-6 and IL-10. Therefore, we hypothesized that S1PR2 may have certain role to play in ApoM-S1P treatment to HUVECs. S1PR2 has potential utility in the drug targeted treatment of vascular inflammatory disorders [33]. Consistent with our hypothesis, data in previous study manifested that the pro-inflammatory impacts of S1P on HUVECs are largely mediated by S1PR2 [34]. The anti-inflammatory function of S1PR2 was also discovered in inflammatory bowel disease, as data showed that miR-126 could down-regulate S1PR2 expression and thus inhibit the activation of its downstream pathway PI3K/AKT signal pathway [35].

Although we found the implication of S1PR2 in pyroptosis of HUVECs, the possible downstream mechanism of S1PR2 in regulating pyroptosis of HUVECs remains to be clarified. PI3K/AKT is a downstream signaling pathway of S1P receptors, which is essential for vascular inflammation [21]. PI3K/AKT pathway-related proteins are the most frequently altered in human cancers, which associated with tumorigenesis, cellular transformation, drug resistance, and cancer progression [36]. Previous research has discovered that the alteration of PI3K/AKT pathway plays very important prognostic and predictive roles in colorectal cancer [37]. What’s more, growing evidences found that S1PR2 have a great impact on PI3K/AKT pathway. For instance, S1PR2 mediates endothelial cells dysfunction through PI3K/AKT pathway under high glucose condition [38]. The regulation of S1P/S1PR on AS progression is complicated and the protective role of ApoM-S1P on pyroptosis of HUVECs may have certain association with cellular signal pathway. S1PR2 has been found to associate with the G proteins Gα12/13, Gαq, or Gαi, while the coupling of S1PR2 with G proteins could further trigger the activation of PI3K/AKT pathway [39]. Although this study found the regulatory role of S1PR2 on p-PI3K and p-AKT levels, considering the complication of pathological courses of HUVEC injury and AS, we can only speculate a possible hypothesis and more studies are required to explore the possible mechanism herein. Due to time and budget limitations, we failed to set up an in vivo model to verify our speculation. But this indicates a promising future direction for our future studies.

Conclusion

Collectively, in this study, the results concluded from above findings indicated that ApoM-S1P inhibits TNF-α-induced inflammation response in HUVECs through binding to S1PR2 to activate PI3K/AKT pathway. In this regards, we supported the beneficial role of ApoM-S1P in attenuating HUVECs injury. Nonetheless, these results must be interpreted with caution, and more studies are required to validate the results of current study.

Notes

Acknowledgements

Thanks for all the supports and contributions of participators.

Authors’ contributions

YL had full access to all of the data in the study and takes responsibility for the integrity of the data, the accuracy of the data analysis and wrote the manuscript draft. YL performed research. YL and LT contributed substantially to the study design and the writing of the manuscript. All authors read and approved the final version of the manuscript.

Funding

This work was supported by the Natural Science Foundation of Hunan Province (14JJ7006), the Science and Technology Innovation Planning Project of Hunan Province (2017SK50104).These funding bodies didn’t play the role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare there is no conflict of interests.

References

  1. 1.
    Li D, Tan Y. TIPE2 suppresses atherosclerosis by exerting a protective effect on macrophages via the inhibition of the Akt signaling pathway. Exp Ther Med. 2019;17(4):2937–44.PubMedPubMedCentralGoogle Scholar
  2. 2.
    Wu MY, Li CJ, Hou MF, Chu PY. New insights into the role of inflammation in the pathogenesis of atherosclerosis. Int J Mol Sci. 2017;18(10):1–18.Google Scholar
  3. 3.
    Li B, Li W, Li X, Zhou H. Inflammation: a novel therapeutic target/direction in atherosclerosis. Curr Pharm Des. 2017;23(8):1216–27.CrossRefGoogle Scholar
  4. 4.
    Yao X, Yan C, Zhang L, Li Y, Wan Q. LncRNA ENST00113 promotes proliferation, survival, and migration by activating PI3K/Akt/mTOR signaling pathway in atherosclerosis. Medicine (Baltimore). 2018;97(16):e0473.CrossRefGoogle Scholar
  5. 5.
    Xu YJ, Zheng L, Hu YW, Wang Q. Pyroptosis and its relationship to atherosclerosis. Clin Chim Acta. 2018;476:28–37.CrossRefGoogle Scholar
  6. 6.
    Li P, Zhong X, Li J, Liu H, Ma X, He R, Zhao Y. MicroRNA-30c-5p inhibits NLRP3 inflammasome-mediated endothelial cell pyroptosis through FOXO3 down-regulation in atherosclerosis. Biochem Biophys Res Commun. 2018;503(4):2833–40.CrossRefGoogle Scholar
  7. 7.
    Wu X, Zhang H, Qi W, Zhang Y, Li J, Li Z, Lin Y, Bai X, Liu X, Chen X, et al. Nicotine promotes atherosclerosis via ROS-NLRP3-mediated endothelial cell pyroptosis. Cell Death Dis. 2018;9(2):171.CrossRefGoogle Scholar
  8. 8.
    Yuan YY, Xie KX, Wang SL, Yuan LW. Inflammatory caspase-related pyroptosis: mechanism, regulation and therapeutic potential for inflammatory bowel disease. Gastroenterol Rep (Oxf). 2018;6(3):167–76.CrossRefGoogle Scholar
  9. 9.
    Zhang Y, Liu X, Bai X, Lin Y, Li Z, Fu J, Li M, Zhao T, Yang H, Xu R, et al. Melatonin prevents endothelial cell pyroptosis via regulation of long noncoding RNA MEG3/miR-223/NLRP3 axis. J Pineal Res. 2018;64(2):1–27.CrossRefGoogle Scholar
  10. 10.
    Feuerborn R, Besser M, Poti F, Burkhardt R, Weissen-Plenz G, Ceglarek U, Simoni M, Proia RL, Freise H, Nofer JR. Elevating endogenous Sphingosine-1-phosphate (S1P) levels improves endothelial function and ameliorates atherosclerosis in low density lipoprotein receptor-deficient (LDL-R−/−) mice. Thromb Haemost. 2018;118(8):1470–80.CrossRefGoogle Scholar
  11. 11.
    Wang X, Zhan E, Lu G, Mu Q, Zhang T, Yang N. Sphingosine-1-phosphate improves the biological features of mouse bone marrow-derived EPCs partially through PI3K/AKT/eNOS/NO pathway. Molecules. 2019;24(13):1–12.Google Scholar
  12. 12.
    Zhao S, Adebiyi MG, Zhang Y, Couturier JP, Fan X, Zhang H, Kellems RE, Lewis DE, Xia Y. Sphingosine-1-phosphate receptor 1 mediates elevated IL-6 signaling to promote chronic inflammation and multitissue damage in sickle cell disease. FASEB J. 2018;32(5):2855–65.CrossRefGoogle Scholar
  13. 13.
    Proia RL, Hla T. Emerging biology of sphingosine-1-phosphate: its role in pathogenesis and therapy. J Clin Invest. 2015;125(4):1379–87.CrossRefGoogle Scholar
  14. 14.
    Zhao J, Garcia D, Gartung A, Lee MJ. Sphingosine-1-phosphate receptor subtype 2 signaling in endothelial senescence-associated functional impairments and inflammation. Curr Atheroscler Rep. 2015;17(5):504.CrossRefGoogle Scholar
  15. 15.
    Huang XS, Zhao SP, Hu M, Luo YP. Apolipoprotein M likely extends its anti-atherogenesis via anti-inflammation. Med Hypotheses. 2007;69(1):136–40.CrossRefGoogle Scholar
  16. 16.
    Terao R, Honjo M, Aihara M. Apolipoprotein M inhibits Angiogenic and inflammatory response by Sphingosine 1-phosphate on retinal pigment epithelium cells. Int J Mol Sci. 2017;19(1):1–14.CrossRefGoogle Scholar
  17. 17.
    Liu M, Frej C, Langefeld CD, Divers J, Bowden DW, Carr JJ, Gebre AK, Xu J, Larsson B, Dahlback B, et al. Plasma Apolipoprotein M and Sphingosine-1-phosphate levels are inversely associated with mortality in African Americans with type 2 diabetes mellitus. J Lipid Res. 2019;60(8):1425–31.CrossRefGoogle Scholar
  18. 18.
    Bosteen MH, Madsen Svarrer EM, Bisgaard LS, Martinussen T, Madsen M, Nielsen LB, Christoffersen C, Pedersen TX. Effects of apolipoprotein M in uremic atherosclerosis. Atherosclerosis. 2017;265:93–101.CrossRefGoogle Scholar
  19. 19.
    Li X, Zhang Q, Zhang R, Cheng N, Guo N, Liu Y, Cai J, Yuan D. Down-regulation of Cx43 expression on PIH-HUVEC cells attenuates monocyte-endothelial adhesion. Thromb Res. 2019;179:104–13.CrossRefGoogle Scholar
  20. 20.
    Zhou P, Xie W, Luo Y, Lu S, Dai Z, Wang R, Sun G, Sun X. Protective Effects of Total Saponins of Aralia elata (Miq.) on Endothelial Cell Injury Induced by TNF-alpha via Modulation of the PI3K/Akt and NF-kappaB Signalling Pathways. Int J Mol Sci. 2018;20(1):e36.CrossRefGoogle Scholar
  21. 21.
    Zheng Z, Zeng Y, Zhu X, Tan Y, Li Y, Li Q, Yi G. ApoM-S1P modulates ox-LDL-induced inflammation through the PI3K/Akt signaling pathway in HUVECs. Inflammation. 2019;42(2):606–17.CrossRefGoogle Scholar
  22. 22.
    Burja B, Kuret T, Janko T, Topalovic D, Zivkovic L, Mrak-Poljsak K, Spremo-Potparevic B, Zigon P, Distler O, Cucnik S, et al. Olive leaf extract attenuates inflammatory activation and DNA damage in human arterial endothelial cells. Front Cardiovasc Med. 2019;6(56):1–11.Google Scholar
  23. 23.
    Ruiz M, Frej C, Holmer A, Guo LJ, Tran S, Dahlback B. High-density lipoprotein-associated Apolipoprotein M limits endothelial inflammation by delivering Sphingosine-1-phosphate to the Sphingosine-1-phosphate receptor 1. Arterioscler Thromb Vasc Biol. 2017;37(1):118–29.CrossRefGoogle Scholar
  24. 24.
    Bergsbaken T, Fink SL, Cookson BT. Pyroptosis: host cell death and inflammation. Nat Rev Microbiol. 2009;7(2):99–109.CrossRefGoogle Scholar
  25. 25.
    Obinata H, Hla T. Sphingosine 1-phosphate and inflammation. Int Immunol. 2019;31(9):617–25.CrossRefGoogle Scholar
  26. 26.
    Johnston TP. Poloxamer 407 increases soluble adhesion molecules, ICAM-1, VCAM-1 and E-selectin, in C57BL/6 mice. J Pharm Pharmacol. 2009;61(12):1681–8.PubMedGoogle Scholar
  27. 27.
    Ragab SM, Safan MA, Obeid OM, Sherief AS. Lipoprotein-associated phospholipase A2 (Lp-PLA2) and tumor necrosis factor-alpha (TNF-alpha) and their relation to premature atherosclerosis in beta-thalassemia children. Hematology. 2015;20(4):228–38.CrossRefGoogle Scholar
  28. 28.
    Christoffersen C, Federspiel CK, Borup A, Christensen PM, Madsen AN, Heine M, Nielsen CH, Kjaer A, Holst B, Heeren J, et al. The Apolipoprotein M/S1P Axis controls triglyceride metabolism and Brown fat activity. Cell Rep. 2018;22(1):175–88.CrossRefGoogle Scholar
  29. 29.
    Ruiz M, Okada H, Dahlback B. HDL-associated ApoM is anti-apoptotic by delivering sphingosine 1-phosphate to S1P1 & S1P3 receptors on vascular endothelium. Lipids Health Dis. 2017;16(1):36.CrossRefGoogle Scholar
  30. 30.
    Christensen PM, Liu CH, Swendeman SL, Obinata H, Qvortrup K, Nielsen LB, Hla T, Di Lorenzo A, Christoffersen C. Impaired endothelial barrier function in apolipoprotein M-deficient mice is dependent on sphingosine-1-phosphate receptor 1. FASEB J. 2016;30(6):2351–9.CrossRefGoogle Scholar
  31. 31.
    Li X, Fang P, Li Y, Kuo YM, Andrews AJ, Nanayakkara G, Johnson C, Fu H, Shan H, Du F, et al. Mitochondrial reactive oxygen species mediate Lysophosphatidylcholine-induced endothelial cell activation. Arterioscler Thromb Vasc Biol. 2016;36(6):1090–100.CrossRefGoogle Scholar
  32. 32.
    Zhu Y, Luo G, Jiang B, Yu M, Feng Y, Wang M, Xu N, Zhang X. Apolipoprotein M promotes proliferation and invasion in non-small cell lung cancers via upregulating S1PR1 and activating the ERK1/2 and PI3K/AKT signaling pathways. Biochem Biophys Res Commun. 2018;501(2):520–6.CrossRefGoogle Scholar
  33. 33.
    Zhang G, Yang L, Kim GS, Ryan K, Lu S, O'Donnell RK, Spokes K, Shapiro N, Aird WC, Kluk MJ, et al. Critical role of sphingosine-1-phosphate receptor 2 (S1PR2) in acute vascular inflammation. Blood. 2013;122(3):443–55.CrossRefGoogle Scholar
  34. 34.
    Ren K, Lu YJ, Mo ZC, Liu X, Tang ZL, Jiang Y, Peng XS, Li L, Zhang QH, Yi GH. ApoA-I/SR-BI modulates S1P/S1PR2-mediated inflammation through the PI3K/Akt signaling pathway in HUVECs. J Physiol Biochem. 2017;73(2):287–96.CrossRefGoogle Scholar
  35. 35.
    Chen T, Xue H, Lin R, Huang Z. MiR-126 impairs the intestinal barrier function via inhibiting S1PR2 mediated activation of PI3K/AKT signaling pathway. Biochem Biophys Res Commun. 2017;494(3–4):427–32.CrossRefGoogle Scholar
  36. 36.
    Mayer IA, Arteaga CL. The PI3K/AKT pathway as a target for Cancer treatment. Annu Rev Med. 2016;67:11–28.CrossRefGoogle Scholar
  37. 37.
    Danielsen SA, Eide PW, Nesbakken A, Guren T, Leithe E, Lothe RA. Portrait of the PI3K/AKT pathway in colorectal cancer. Biochim Biophys Acta. 2015;1855(1):104–21.PubMedGoogle Scholar
  38. 38.
    Liu W, Liu B, Liu S, Zhang J, Lin S. Sphingosine-1-phosphate receptor 2 mediates endothelial cells dysfunction by PI3K-Akt pathway under high glucose condition. Eur J Pharmacol. 2016;776:19–25.CrossRefGoogle Scholar
  39. 39.
    Johnstone EA-SK, Tan C, et al. Vitamin D regulates extravillous trophoblast migration by inhibiting sphingosine-1-phosphate (S1P) signalling via S1P receptor 2. BioScientifica. 2015;38:1–13.Google Scholar

Copyright information

© The Author(s). 2019

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors and Affiliations

  1. 1.International Medical Center, Geriatric Department, National Clinical Research Center for Geriatric DisordersXiangya Hospital, Central South UniversityChangshaPeople’s Republic of China
  2. 2.Department of CardiologyChangsha Central HospitalChangshaPeople’s Republic of China

Personalised recommendations